Introduction
Sacituzumab govitecan-hziy (Trodelvy; Gilead Sciences) is a first-in-class Trop-2-directed antibody–drug conjugate (ADC) approved for unresectable locally advanced or metastatic triple-negative breast cancer after prior systemic therapy, and for unresectable locally advanced or metastatic hormone receptor–positive/HER2-negative breast cancer after endocrine-based therapy and additional prior systemic therapy in the metastatic setting. This evaluation synthesizes pivotal trial data, recent regulatory updates, real-world evidence, and guideline positioning to assess net clinical benefit and practical adoption considerations.
Clinical Efficacy by Indication and Line of Therapy
Metastatic Triple-Negative Breast Cancer
The phase 3 ASCENT trial (N=468 without baseline brain metastases) established sacituzumab govitecan's superiority over single-agent chemotherapy in relapsed/refractory mTNBC after ≥2 prior therapies1. Sacituzumab govitecan demonstrated median overall survival (OS) of 12.1 months versus 6.7 months with chemotherapy (hazard ratio [HR] 0.48; 95% CI, 0.38–0.59; P<0.001) and median progression-free survival (PFS) of 5.6 months versus 1.7 months (HR 0.41; 95% CI, 0.32–0.52; P<0.001)1. The objective response rate (ORR) was 35% versus 5%1, representing a seven-fold improvement. Subgroup analyses confirmed benefit in second-line settings (median PFS 5.7 vs. 1.5 months; HR 0.41) and in patients without initial TNBC diagnosis (median OS 12.4 vs. 6.7 months; HR 0.44)89.
The ASCENT-03 trial, presented at ASCO 2025, evaluated sacituzumab govitecan as first-line therapy in patients ineligible for PD-1/PD-L1 inhibitors (PD-L1-negative [CPS <10] or contraindications)19. The trial demonstrated median PFS of 9.7 months versus 6.9 months with chemotherapy (HR 0.62; 95% CI, 0.50–0.77; P<0.001), with ORR of 48% versus 46% but median duration of response of 12.2 months versus 7.2 months19. Grade ≥3 adverse events occurred in 66% versus 62% of patients, with discontinuation rates of 4% versus 12%, favoring sacituzumab govitecan19. Based on these data, the NCCN Guidelines (Version 1.2026, updated February 2026) now designate sacituzumab govitecan monotherapy as a Category 1 preferred first-line option for PD-L1-negative mTNBC without germline BRCA1/2 mutations18.
At ASCO 2025, the ASCENT-04/KEYNOTE-D19 trial reported that sacituzumab govitecan plus pembrolizumab achieved median PFS of 11.2 months versus 7.8 months with chemotherapy plus pembrolizumab in PD-L1-positive disease, with a 35% lower risk of progression and median duration of response of 16.5 months versus 9.2 months27. NCCN guidelines now classify this combination as Category 2A preferred for PD-L1-positive (CPS ≥10) first-line mTNBC18. ESMO guidelines position sacituzumab govitecan as the preferred treatment option after previous chemotherapy with an ESMO-MCBS v2.0 score of 526.
HR-Positive/HER2-Negative Metastatic Breast Cancer
The TROPiCS-02 trial (N=543) randomized heavily pretreated HR+/HER2− patients (median 3 prior chemotherapy lines; 99% prior CDK4/6 inhibitor) to sacituzumab govitecan or chemotherapy425. The final OS analysis demonstrated median OS of 14.5 months versus 11.2 months (HR 0.79; 95% CI, 0.65–0.95; nominal P=0.01), with OS rates at 12 months of 60.9% versus 47.1% and at 24 months of 25.6% versus 21.1%24. Median PFS was 5.5 months versus 4.0 months (HR 0.66; 95% CI, 0.53–0.83; P=0.0003)425, with PFS rates at 12 months of 21% versus 7%4. ORR was 21% versus 14%, with median duration of response of 7.4 versus 5.6 months25.
A meta-analysis pooling TROPiCS-02 and EVER-132-002 (N=874) confirmed median OS of 16.20 months versus 12.71 months (HR 0.66; 95% CI, 0.55–0.80; P<0.001) in the overall population and 15.38 months versus 11.50 months in the prior CDK4/6i-treated subgroup22. Importantly, in fast-progressors (prior CDK4/6i duration ≤12 months), sacituzumab govitecan achieved median OS of 16.0 months versus 11.10 months (HR 0.77; P=0.001)22.
HER2 immunohistochemistry post hoc analysis from TROPiCS-02 revealed benefit across HER2-null (median OS 13.6 vs. 10.8 months; HR 0.86) and HER2-low subgroups (median OS 15.4 vs. 11.5 months; HR 0.74)24. Quality-adjusted analysis demonstrated mean Q-TWiST of 9.7 months versus 8.1 months (difference 1.6 months; P=0.0067), with a 10.8% relative gain meeting clinical importance thresholds21. Patient-reported outcomes showed significant improvements in physical functioning, pain, and dyspnea, with extended time to deterioration in global health status (HR 0.76; P=0.005)23.
ASCO guidelines now recommend sacituzumab govitecan for HR+/HER2− patients refractory to endocrine therapy and having received ≥2 prior chemotherapy lines for metastatic disease28.
Urothelial Carcinoma
Sacituzumab govitecan received accelerated FDA approval on April 13, 2021, for locally advanced or metastatic urothelial cancer (mUC) after platinum-containing chemotherapy and PD-1/PD-L1 inhibitor, based on the single-arm TROPHY trial (N=112)6. The trial demonstrated ORR of 27.7% (95% CI, 19.6–36.9) with complete responses in 5.4% and median duration of response of 7.2 months6. However, the confirmatory trial failed to demonstrate clinical benefit, and the indication was voluntarily withdrawn on November 20246.
Safety Profile and Risk Management
Adverse Events of Special Interest
The most significant toxicities are myelosuppression and gastrointestinal adverse events. In ASCENT, grade ≥3 neutropenia occurred in 51% of sacituzumab govitecan-treated patients versus 33% with chemotherapy, with febrile neutropenia in 6% versus 2%1. Grade ≥3 diarrhea occurred in 10% versus <1%1. All-grade adverse events included neutropenia (64%), fatigue (65%), diarrhea (59%), nausea (57%), and alopecia (47%)2.
In TROPiCS-02, grade ≥3 neutropenia was 51% versus 38% with chemotherapy, and grade ≥3 diarrhea was 9% versus 1%425. Treatment discontinuation due to adverse events was 5–6% in breast cancer trials125, substantially lower than chemotherapy (4–12%)1925.
Boxed Warnings and Monitoring Requirements
The FDA label (updated March 2025) carries boxed warnings for neutropenia and diarrhea15. Key monitoring mandates include:
- Withhold sacituzumab govitecan for absolute neutrophil count (ANC) <1500/mm³ on Day 1 or <1000/mm³ on Day 815
- Primary G-CSF prophylaxis recommended for patients at increased risk of febrile neutropenia15
- At onset of diarrhea, evaluate for infectious causes; if negative, promptly initiate loperamide15
- Withhold for grade 3–4 diarrhea until resolved to ≤grade 115
Pharmacogenomic Considerations
Patients homozygous for UGT1A1*28 experience significantly higher toxicity: grade ≥3 neutropenia in 59% versus 47–53% in heterozygotes/wild-type, febrile neutropenia in 18% versus 3–5%, and grade ≥3 anemia in 15% versus 4–6%2. The FDA label recommends increased monitoring for UGT1A1*28/*28 carriers but does not mandate dose reduction15.
Real-World Toxicity Management
A multi-institutional U.S. cohort (N=115) demonstrated that 51.3% of patients required dose reductions and 13.2% discontinued due to adverse events11, rates substantially higher than in ASCENT (22% dose reductions, 5% discontinuations)1. Grade ≥3 adverse events occurred in 50.9%, with neutropenia (35.7%), anemia (27.0%), and vomiting (16.5%) most common11. Notably, 47% received G-CSF support (22.6% primary prophylaxis, 24.3% secondary)11, and median relative dose intensity was 92% despite modifications11. Importantly, dose intensity did not correlate with response rates, supporting flexible dose management11.
Comparative Effectiveness and Sequencing Strategies
Cross-ADC Sequencing
A large real-world analysis (N=4,030) comparing sacituzumab govitecan and trastuzumab deruxtecan (T-DXd) in HER2-negative breast cancer revealed T-DXd superiority in HR+ disease (time-on-treatment [TOT] 4.9 vs. 3.0 months; HR 0.616; P<0.0001) but no significant difference in TNBC (TOT 4.1 vs. 3.4 months; HR 0.912; P=0.237)14. Critically, in HR−/HER2-null disease, sacituzumab govitecan-first sequencing followed by T-DXd yielded superior outcomes: cumulative TOT of 11.7 versus 7.4 months (HR 0.478; P<0.0001) and OS of 19.7 versus 11.8 months14.
Among 26 HER2-low mTNBC patients receiving T-DXd after sacituzumab govitecan, ORR to T-DXd was 34.8% with median PFS of 7 months11. Importantly, cross-ADC toxicity did not recur: three patients discontinuing sacituzumab govitecan for grade ≥3 fatigue, anemia, or diarrhea experienced no recurrence of these toxicities with T-DXd11.
Limited data on sacituzumab govitecan after enfortumab vedotin (EV) in urothelial cancer showed ORR of only 11% and median OS of 6.0 months13, suggesting potential cross-resistance.
Practical Adoption Factors
Dosing and Administration
The standard regimen is 10 mg/kg intravenously on Days 1 and 8 of 21-day cycles615. The first infusion is administered over 3 hours; subsequent infusions over 1–2 hours if tolerated15. Premedication for infusion reactions and antiemetic prophylaxis are recommended15. Hypersensitivity reactions within 24 hours occurred in 35% of patients (grade 3–4 in 2%)15.
Patient Selection and Real-World Performance
Real-world cohorts demonstrate maintained activity in heavily pretreated, diverse populations despite higher toxicity. In a U.S. cohort with median 2 prior metastatic therapies (range 0–8) and 56% primary refractory disease, sacituzumab govitecan achieved ORR of 27.8%, median PFS of 4.8 months, and median OS of 9.6 months11. Primary refractory disease negatively impacted outcomes (OS 8.1 vs. 13.7 months; P=0.02)11. Age ≥65 years did not significantly increase grade ≥3 adverse events (25.6% vs. 40.8% in younger patients)11.
Brain metastases were not associated with efficacy differences but significantly increased grade ≥3 adverse events and treatment discontinuation (P<0.001 and P=0.015, respectively)11.
Regulatory and Guideline Landscape
Beyond U.S. FDA approval, sacituzumab govitecan received European Commission authorization in November 2021 for pretreated mTNBC; the HR-positive/HER2-negative metastatic breast cancer indication was added later in 2023. A Type II variation for use in combination with pembrolizumab was under evaluation as of late 2025 1620. China NMPA approval was granted in June 2022 for mTNBC17.
The NCCN Guidelines (February 2026) represent the most significant recent update, elevating sacituzumab govitecan to Category 1 first-line monotherapy for PD-L1-negative mTNBC and Category 2A first-line combination with pembrolizumab for PD-L1-positive disease18.
Conclusion
Sacituzumab govitecan demonstrates substantial survival benefits across mTNBC and HR+/HER2− metastatic breast cancer, with OS improvements of 5.4 months (ASCENT) and 3.3 months (TROPiCS-02) compared to chemotherapy. The toxicity profile—dominated by manageable neutropenia and diarrhea—is acceptable given limited alternatives in these heavily pretreated populations, with low discontinuation rates (5–6%) supporting tolerability. The Category 1 NCCN designation for first-line PD-L1-negative mTNBC reflects strong evidence from ASCENT-03 and positions sacituzumab govitecan as a backbone therapy. In HR+/HER2− disease, sacituzumab govitecan fills an unmet need after CDK4/6 inhibitor progression, particularly for fast-progressors and HER2-null patients. Sequencing with T-DXd appears favorable, with biology-informed selection (sacituzumab govitecan-first in HR−/HER2-null) optimizing outcomes. Real-world adoption requires institutional capacity for proactive toxicity management—G-CSF prophylaxis, prompt antidiarrheal intervention, and dose flexibility—but offers clinically meaningful disease control with preserved quality of life.